tradingkey.logo

Adverum Biotechnologies Inc <ADVM.OQ> expected to post a loss of $1.81 a share - Earnings Preview

ReutersMay 14, 2025 11:01 AM
  • Adverum Biotechnologies Inc ADVM.OQ ADVM.O is expected to show no change in quarterly revenue when it reports results on May 16 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Adverum Biotechnologies Inc is for a loss of $1.81 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Adverum Biotechnologies Inc is $24.00​, above​ its last closing price of $2.22. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-1.36

-1.96

Missed

-44.2

Sep. 30 2024

-1.29

-1.31

-1.30

Beat

0.5

Jun. 30 2024

-1.44

-1.47

-0.89

Beat

39.4​

Mar. 31 2024

-1.55

-1.40

-1.50

Missed

-6.8

​​Dec. 31 2023

-3.35

-3.37

-2.30

Beat

31.7

Sep. 30 2023

-3.06

-3.15

-3.30

Missed

-4.7​

Jun. 30 2023

-3.12

-3.29

-3.10

Beat

5.7

Mar. 31 2023

-3.20

-3.20

-2.90

Beat

9.5

This summary was machine generated May 14 at 11:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles